Neoadjuvant Trastuzumab, Docetaxel, and Carboplatin (TCH) for human epidermal growth factor receptor -2 (Her-2) positive breast cancer: pathological tumour response rates in an Irish teaching hospital
Jayaram, AK, King, F, Dunne, B, Collins, Ian, Boyle, T and Kennedy, MJ 2010, Neoadjuvant Trastuzumab, Docetaxel, and Carboplatin (TCH) for human epidermal growth factor receptor -2 (Her-2) positive breast cancer: pathological tumour response rates in an Irish teaching hospital, in ESMO 2010 : Proceedings of the 35th ESMO Congress, Oxford University Press, Oxford, Eng., pp. viii113-viii113, doi: 10.1093/annonc/mdq517.
Attached Files
Name
Description
MIMEType
Size
Downloads
Title
Neoadjuvant Trastuzumab, Docetaxel, and Carboplatin (TCH) for human epidermal growth factor receptor -2 (Her-2) positive breast cancer: pathological tumour response rates in an Irish teaching hospital
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.
Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO.
If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.
Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.